Trial reportClinical cardiology2012
Does nebivolol prevent contrast-induced nephropathy in humans?
Trial report in Clinical cardiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Guideline on the use of iodinated contrast media in patients with kidney disease 2018.Clinical and experimental nephrology · 2020Guideline
- Effectiveness of contrast-associated acute kidney injury prevention methods; a systematic review and network meta-analysis.BMC nephrology · 2018Pooled it
- Update on Contrast-Induced Nephropathy: Recent Developments in Its Prevention, Early Diagnosis, and Therapy.Medicina (Kaunas, Lithuania) · 2026Review
- Ameliorative effect of nebivolol in doxorubicin-induced cardiotoxicity.Journal of medicine and life · 2023Article
- Observational
- Guideline on the use of iodinated contrast media in patients with kidney disease 2018.Japanese journal of radiology · 2020Article
- Article
- Contrast induced acute kidney injury and the role of beta-blockers in its prevention.Journal of thoracic disease · 2019Article
- Protective effects of nebivolol from oxidative stress to prevent hypertension-related target organ damage.Journal of human hypertension · 2017Review
- Update on the renal toxicity of iodinated contrast drugs used in clinical medicine.Drug, healthcare and patient safety · 2017Review
- Effectiveness of N-Acetylcysteine for the Prevention of Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of the American Heart Association · 2016Article
- The potential use of biomarkers in predicting contrast-induced acute kidney injury.International journal of nephrology and renovascular disease · 2016Review
- Periprocedural Nebivolol for the Prevention of Contrast-Induced Acute Kidney Injury: A Systematic Review and Meta-analysis.North American journal of medical sciences · 2015Article
- Comparison of Carvedilol and Metoprolol for Preventing Contrast-Induced Nephropathy after Coronary Angiography.Cardiorenal medicine · 2015Article
- The protective effect of single dose tadalafil in contrast-induced nephropathy: an experimental study.Anatolian journal of cardiology · 2015Article
- A clinical study about contrast nephropathy: risk factors and the role of beta blockers.Anatolian journal of cardiology · 2015Article
- Pharmacological strategies to prevent contrast-induced acute kidney injury.BioMed research international · 2014Review
- Side effects of radiographic contrast media: pathogenesis, risk factors, and prevention.BioMed research international · 2014Review
- Prevention of contrast-induced nephropathy through a knowledge of its pathogenesis and risk factors.TheScientificWorldJournal · 2014Review
- Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan.Integrated blood pressure control · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn experimental study showed that nebivolol is an effective agent in contrast-induced nephropathy (CIN) prophylaxis. HYPOTHESIS: We hypothesized that prophylactic nebivolol use had protective effects on renal function in human beings subjected to iodinated contrast agent since it has vasodilatory effect and antioxidant properties.
methodsThe present study enrolled 120 patients scheduled for coronary angiography and ventriculography. All patients were hydrated with intravenous isotonic saline. The patients in group I received 600 mg N-acetylcysteine every 12 hours for 4 days. The patients in group II received 5 mg nebivolol every 24 hours for 4 days. The patients in group III were only hydrated. The primary endpoint was the occurrence of CIN. The secondary endpoint was the change in serum creatinine (Cr) levels at 2 days and 5 days after the contrast exposure.
resultsNine (22.5%) patients in group I developed CIN, as did 8 patients (20.0%) in group II and 11 patients (27.5%) in group III (P = 0.72). Changes in mean Cr level from baseline to day 2 were not statistically significant in all groups. However, we detected a statistically significant increase in mean Cr levels at day 5 compared with baseline levels in group I and group III (from 1.42 ± 0.13 to 1.52 ± 0.26, p2 = 0.02; and from 1.43 ± 0.14 to 1.55 ± 0.30, p2 = 0.01, respectively). Although an increase was detected in mean Cr level from baseline to the 5-day Cr level in group II, this did not reach statistical significance (from 1.40 ± 0.12 to 1.48 ± 0.23, P = 0.06).
conclusionsPretreatment with nebivolol is protective against nephrotoxic effects of contrast media.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.